Molecular studies indicated that p53 mutations account for 20–32% of chRCC cases, phosphatase and tension homolog (PTEN) mutations were observed in almost 6–9% of patients, TERT promoter mutations/rearrangements in 12% of cases, and mitochondrial DNA alterations were rarely observed [21]. The gene discussed is TP53; the disease is chromophobe renal cell carcinoma.